Suppression of MR1 by human cytomegalovirus inhibits MAIT cell activation.

MAIT cells MHC class I related protein-1 MR1 herpesvirus human cytomegalovirus immune modulation mucosal-associated invariant T cells

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 25 11 2022
accepted: 25 01 2023
entrez: 27 2 2023
pubmed: 28 2 2023
medline: 3 3 2023
Statut: epublish

Résumé

The antigen presentation molecule MHC class I related protein-1 (MR1) is best characterized by its ability to present bacterially derived metabolites of vitamin B2 biosynthesis to mucosal-associated invariant T-cells (MAIT cells). Through in vitro human cytomegalovirus (HCMV) infection in the presence of MR1 ligand we investigate the modulation of MR1 expression. Using coimmunoprecipitation, mass spectrometry, expression by recombinant adenovirus and HCMV deletion mutants we investigate HCMV gpUS9 and its family members as potential regulators of MR1 expression. The functional consequences of MR1 modulation by HCMV infection are explored in coculture activation assays with either Jurkat cells engineered to express the MAIT cell TCR or primary MAIT cells. MR1 dependence in these activation assays is established by addition of MR1 neutralizing antibody and CRISPR/Cas-9 mediated MR1 knockout. Here we demonstrate that HCMV infection efficiently suppresses MR1 surface expression and reduces total MR1 protein levels. Expression of the viral glycoprotein gpUS9 in isolation could reduce both cell surface and total MR1 levels, with analysis of a specific US9 HCMV deletion mutant suggesting that the virus can target MR1 using multiple mechanisms. Functional assays with primary MAIT cells demonstrated the ability of HCMV infection to inhibit bacterially driven, MR1-dependent activation using both neutralizing antibodies and engineered MR1 knockout cells. This study identifies a strategy encoded by HCMV to disrupt the MR1:MAIT cell axis. This immune axis is less well characterized in the context of viral infection. HCMV encodes hundreds of proteins, some of which regulate the expression of antigen presentation molecules. However the ability of this virus to regulate the MR1:MAIT TCR axis has not been studied in detail.

Identifiants

pubmed: 36845106
doi: 10.3389/fimmu.2023.1107497
pmc: PMC9950634
doi:

Substances chimiques

Histocompatibility Antigens Class I 0
Minor Histocompatibility Antigens 0
Receptors, Antigen, T-Cell 0
MR1 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1107497

Subventions

Organisme : HCRW_
ID : HCRW_HS-20-30
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S00971X/1
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI148407
Pays : United States

Informations de copyright

Copyright © 2023 Ashley, McSharry, McWilliam, Stanton, Fielding, Mathias, Fairlie, McCluskey, Villadangos, Rossjohn, Abendroth and Slobedman.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Exp Med. 2012 Apr 9;209(4):761-74
pubmed: 22412157
Cell Rep. 2015 Feb 17;10(6):968-982
pubmed: 25683719
Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):10133-8
pubmed: 27543331
Nat Commun. 2018 Jan 9;9(1):125
pubmed: 29317664
PLoS Biol. 2010 Jun 29;8(6):e1000407
pubmed: 20613858
Nat Commun. 2017 Mar 08;8:14599
pubmed: 28272391
Nature. 2014 May 15;509(7500):361-5
pubmed: 24695216
Gastroenterology. 2017 Nov;153(5):1392-1403.e2
pubmed: 28780074
Nat Immunol. 2016 May;17(5):531-7
pubmed: 27043408
J Virol. 2018 Aug 16;92(17):
pubmed: 29950412
Biol Blood Marrow Transplant. 2018 Feb;24(2):242-251
pubmed: 29024803
Arch Virol. 1994;135(1-2):75-87
pubmed: 8198451
PLoS Pathog. 2021 May 3;17(5):e1008807
pubmed: 33939764
Cell. 2015 Jan 15;160(1-2):37-47
pubmed: 25594173
J Virol. 2008 May;82(9):4585-94
pubmed: 18287244
Nat Immunol. 2010 Aug;11(8):701-8
pubmed: 20581831
Infect Immun. 2012 Sep;80(9):3256-67
pubmed: 22778103
Pediatr Transplant. 2013 Sep;17(6):499-509
pubmed: 23890075
Transplantation. 1984 Nov;38(5):465-8
pubmed: 6093296
Clin Vaccine Immunol. 2006 Nov;13(11):1181-4
pubmed: 16957061
Biotechniques. 2008 Dec;45(6):659-62, 664-8
pubmed: 19238796
Proc Natl Acad Sci U S A. 2002 May 28;99(11):7570-5
pubmed: 12032324
J Virol. 1995 Aug;69(8):4830-41
pubmed: 7609050
Front Immunol. 2017 Dec 15;8:1837
pubmed: 29326714
Eur J Immunol. 2018 Oct;48(10):1698-1706
pubmed: 30059139
N Engl J Med. 2001 May 3;344(18):1366-71
pubmed: 11333993
Mol Cells. 2001 Jun 30;11(3):392-8
pubmed: 11459231
Eur J Immunol. 2019 Jan;49(1):133-143
pubmed: 30372518
J Virol. 2010 Jul;84(14):7195-203
pubmed: 20463084
PLoS Negl Trop Dis. 2018 Jan 22;12(1):e0006154
pubmed: 29357366
J Exp Med. 2013 Oct 21;210(11):2305-20
pubmed: 24101382
Nat Immunol. 2018 Mar;19(3):302-314
pubmed: 29476184
J Gen Virol. 2009 Oct;90(Pt 10):2375-2380
pubmed: 19553388
Elife. 2021 Dec 24;10:
pubmed: 34951583
Immunity. 2016 Jan 19;44(1):32-45
pubmed: 26795251
Elife. 2021 Mar 16;10:
pubmed: 33724188
Infect Chemother. 2013 Sep;45(3):260-71
pubmed: 24396627
J Clin Invest. 2010 Sep;120(9):3191-208
pubmed: 20679731
Rev Infect Dis. 1991 Mar-Apr;13(2):315-29
pubmed: 1645882
Arch Dis Child. 1992 Jul;67(7 Spec No):779-83
pubmed: 1325757
J Clin Virol. 2009 Dec;46 Suppl 4:S6-10
pubmed: 19800841
Mucosal Immunol. 2017 Jan;10(1):35-45
pubmed: 27049062
Immunity. 1997 May;6(5):613-21
pubmed: 9175839
PLoS Pathog. 2013;9(10):e1003681
pubmed: 24130485
Eur J Immunol. 2016 Jul;46(7):1600-14
pubmed: 27105778
Cell Mol Immunol. 2015 Mar;12(2):139-53
pubmed: 25418469
Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):E5434-E5443
pubmed: 28630305
J Exp Med. 1999 Jun 21;189(12):1907-21
pubmed: 10377186
J Infect Dis. 2017 Jun 1;215(11):1673-1683
pubmed: 28368496
Scand J Infect Dis Suppl. 1995;99:82-7
pubmed: 8668948
Rev Med Virol. 2010 Jul;20(4):202-13
pubmed: 20564615
PLoS Biol. 2009 Mar 10;7(3):e54
pubmed: 19278296
Cell Rep. 2020 Mar 3;30(9):2948-2962.e4
pubmed: 32130899
J Immunol. 2016 Aug 1;197(3):971-82
pubmed: 27307560
Nat Commun. 2021 Apr 6;12(1):2061
pubmed: 33824318
J Virol. 2009 Dec;83(23):12345-54
pubmed: 19793804
J Leukoc Biol. 2016 Jul;100(1):233-40
pubmed: 27034405
J Virol. 1996 Dec;70(12):8402-10
pubmed: 8970961
Nat Commun. 2022 May 11;13(1):2603
pubmed: 35546552
Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):E3119-28
pubmed: 23898209
Breast Cancer Res. 2018 Sep 12;20(1):111
pubmed: 30208917
Nature. 2012 Nov 29;491(7426):717-23
pubmed: 23051753
J Gen Virol. 2001 Apr;82(Pt 4):855-863
pubmed: 11257191
J Infect Dis. 2002 Feb 1;185(3):273-82
pubmed: 11807708
J Exp Med. 2014 Jul 28;211(8):1585-600
pubmed: 25049336
J Infect Dis. 2023 Feb 1;227(3):391-401
pubmed: 34648018
Int J Hematol. 2018 Jul;108(1):66-75
pubmed: 29582333
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
Eur J Immunol. 2014 Jan;44(1):195-203
pubmed: 24019201
J Exp Med. 2010 Aug 30;207(9):2033-41
pubmed: 20713594
Nat Commun. 2014 May 15;5:3866
pubmed: 24832684
Nature. 2003 Mar 13;422(6928):164-9
pubmed: 12634786
PLoS One. 2015 Apr 20;10(4):e0124659
pubmed: 25894562
Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6904-9
pubmed: 9192664
Biol Blood Marrow Transplant. 2010 Sep;16(9):1309-14
pubmed: 20353832
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11327-33
pubmed: 8876135
Mol Cell Proteomics. 2005 Dec;4(12):1933-41
pubmed: 16155292
Front Microbiol. 2019 May 28;10:1186
pubmed: 31191499
J Exp Med. 2014 Jul 28;211(8):1601-10
pubmed: 25049333
J Hepatol. 2016 May;64(5):1118-1127
pubmed: 26743076
J Clin Microbiol. 2005 Mar;43(3):1318-24
pubmed: 15750102
Eur J Immunol. 2016 Sep;46(9):2204-10
pubmed: 27296288
Science. 2000 Feb 11;287(5455):1031
pubmed: 10669413
Cell. 1996 Mar 8;84(5):769-79
pubmed: 8625414
PLoS Pathog. 2014 May 01;10(5):e1004058
pubmed: 24787765
J Immunol. 2000 Jan 15;164(2):805-11
pubmed: 10623826
Mucosal Immunol. 2015 Mar;8(2):429-40
pubmed: 25269706
Biol Blood Marrow Transplant. 2017 Nov;23(11):1961-1967
pubmed: 28797778
Blood. 2011 Jan 27;117(4):1250-9
pubmed: 21084709
Immunity. 1997 May;6(5):623-32
pubmed: 9175840

Auteurs

Caroline L Ashley (CL)

Infection, Immunity and Inflammation, School of Medical Sciences, Faculty of Medicine and Health, and the Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.

Brian P McSharry (BP)

Infection, Immunity and Inflammation, School of Medical Sciences, Faculty of Medicine and Health, and the Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
School of Dentistry and Medical Sciences, Faculty of Science and Health, Charles Sturt University, Wagga Wagga, NSW, Australia.

Hamish E G McWilliam (HEG)

Department of Microbiology and Immunology, The Peter Doherty Institute of Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.
Department of Biochemistry and Pharmacology, Institute of Molecular Science and Biotechnology (Bio21), The University of Melbourne, Melbourne, VIC, Australia.

Richard J Stanton (RJ)

Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom.

Ceri A Fielding (CA)

Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom.

Rommel A Mathias (RA)

Infection and Immunity Program, Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia.
Infection and Immunity Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia.

David P Fairlie (DP)

ARC Centre of Excellence for Innovations in Peptide and Protein Science, Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia.

James McCluskey (J)

Department of Microbiology and Immunology, The Peter Doherty Institute of Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.

Jose A Villadangos (JA)

Department of Microbiology and Immunology, The Peter Doherty Institute of Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.
Department of Biochemistry and Pharmacology, Institute of Molecular Science and Biotechnology (Bio21), The University of Melbourne, Melbourne, VIC, Australia.

Jamie Rossjohn (J)

Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Infection and Immunity Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia.

Allison Abendroth (A)

Infection, Immunity and Inflammation, School of Medical Sciences, Faculty of Medicine and Health, and the Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.

Barry Slobedman (B)

Infection, Immunity and Inflammation, School of Medical Sciences, Faculty of Medicine and Health, and the Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH